These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30967303)

  • 1. Kinase inhibitions in pyrido[4,3-h] and [3,4-g]quinazolines: Synthesis, SAR and molecular modeling studies.
    Zeinyeh W; Esvan YJ; Josselin B; Baratte B; Bach S; Nauton L; Théry V; Ruchaud S; Anizon F; Giraud F; Moreau P
    Bioorg Med Chem; 2019 May; 27(10):2083-2089. PubMed ID: 30967303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.
    Tazarki H; Zeinyeh W; Esvan YJ; Knapp S; Chatterjee D; Schröder M; Joerger AC; Khiari J; Josselin B; Baratte B; Bach S; Ruchaud S; Anizon F; Giraud F; Moreau P
    Eur J Med Chem; 2019 Mar; 166():304-317. PubMed ID: 30731399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and preliminary in vitro kinase inhibition evaluation of new diversely substituted pyrido[3,4-g]quinazoline derivatives.
    Zeinyeh W; Esvan YJ; Nauton L; Loaëc N; Meijer L; Théry V; Anizon F; Giraud F; Moreau P
    Bioorg Med Chem Lett; 2016 Sep; 26(17):4327-9. PubMed ID: 27469128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of pyrido[3,4-g]quinazoline derivatives as CMGC family protein kinase inhibitors: Design, synthesis, inhibitory potency and X-ray co-crystal structure.
    Esvan YJ; Zeinyeh W; Boibessot T; Nauton L; Théry V; Knapp S; Chaikuad A; Loaëc N; Meijer L; Anizon F; Giraud F; Moreau P
    Eur J Med Chem; 2016 Aug; 118():170-7. PubMed ID: 27128181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and optimization of an original V-shaped collection of 4-7-disubstituted pyrido[3,2-d]pyrimidines as CDK5 and DYRK1A inhibitors.
    Dehbi O; Tikad A; Bourg S; Bonnet P; Lozach O; Meijer L; Aadil M; Akssira M; Guillaumet G; Routier S
    Eur J Med Chem; 2014 Jun; 80():352-63. PubMed ID: 24793883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of 3,6-diamino-1H-pyrazolo[3,4-b]pyridine derivatives as protein kinase inhibitors.
    Chioua M; Samadi A; Soriano E; Lozach O; Meijer L; Marco-Contelles J
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4566-9. PubMed ID: 19615897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and kinase inhibitory activity of novel substituted indigoids.
    Beauchard A; Laborie H; Rouillard H; Lozach O; Ferandin Y; Le Guével R; Guguen-Guillouzo C; Meijer L; Besson T; Thiéry V
    Bioorg Med Chem; 2009 Sep; 17(17):6257-63. PubMed ID: 19665384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, biological evaluation and molecular modelling studies of 4-anilinoquinazoline derivatives as protein kinase inhibitors.
    Waiker DK; Karthikeyan C; Poongavanam V; Kongsted J; Lozach O; Meijer L; Trivedi P
    Bioorg Med Chem; 2014 Mar; 22(6):1909-15. PubMed ID: 24530227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of new pyridazino[4,5-b]indol-4-ones and pyridazin-3(2H)-one analogs as DYRK1A inhibitors.
    Bruel A; Bénéteau R; Chabanne M; Lozach O; Le Guevel R; Ravache M; Bénédetti H; Meijer L; Logé C; Robert JM
    Bioorg Med Chem Lett; 2014 Nov; 24(21):5037-40. PubMed ID: 25248682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, Docking Study and Kinase Inhibitory Activity of a Number of New Substituted Pyrazolo[3,4-c]pyridines.
    Sklepari M; Lougiakis N; Papastathopoulos A; Pouli N; Marakos P; Myrianthopoulos V; Robert T; Bach S; Mikros E; Ruchaud S
    Chem Pharm Bull (Tokyo); 2017; 65(1):66-81. PubMed ID: 28049917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Kinase Inhibitors via Metal-Catalyzed C⁻H Arylation of 8-Alkyl-thiazolo[5,4-
    Couly F; Harari M; Dubouilh-Benard C; Bailly L; Petit E; Diharce J; Bonnet P; Meijer L; Fruit C; Besson T
    Molecules; 2018 Aug; 23(9):. PubMed ID: 30158487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, biological evaluation and molecular modeling studies of imidazo[1,2-a]pyridines derivatives as protein kinase inhibitors.
    Lawson M; Rodrigo J; Baratte B; Robert T; Delehouzé C; Lozach O; Ruchaud S; Bach S; Brion JD; Alami M; Hamze A
    Eur J Med Chem; 2016 Nov; 123():105-114. PubMed ID: 27474927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and molecular modelling of pyridazinone and phthalazinone derivatives as protein kinases inhibitors.
    Elagawany M; Ibrahim MA; Ali Ahmed HE; El-Etrawy ASh; Ghiaty A; Abdel-Samii ZK; El-Feky SA; Bajorath J
    Bioorg Med Chem Lett; 2013 Apr; 23(7):2007-13. PubMed ID: 23453843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, part I.
    Foucourt A; Hédou D; Dubouilh-Benard C; Désiré L; Casagrande AS; Leblond B; Loäec N; Meijer L; Besson T
    Molecules; 2014 Sep; 19(10):15546-71. PubMed ID: 25268714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
    Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J
    Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Mps1 kinase inhibitors: from purine to pyrrolopyrimidine and quinazoline leads.
    Bursavich MG; Dastrup D; Shenderovich M; Yager KM; Cimbora DM; Williams B; Kumar DV
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6829-33. PubMed ID: 24183538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of DB18, a potent inhibitor of CLK kinases with a high selectivity against DYRK1A kinase.
    Brahmaiah D; Kanaka Durga Bhavani A; Aparna P; Sampath Kumar N; Solhi H; Le Guevel R; Baratte B; Ruchaud S; Bach S; Singh Jadav S; Raji Reddy C; Roisnel T; Mosset P; Levoin N; Grée R
    Bioorg Med Chem; 2021 Feb; 31():115962. PubMed ID: 33422908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, part II.
    Foucourt A; Hédou D; Dubouilh-Benard C; Girard A; Taverne T; Casagrande AS; Désiré L; Leblond B; Besson T
    Molecules; 2014 Sep; 19(10):15411-39. PubMed ID: 25264830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and SAR of new pyrazolo[4,3-h]quinazoline-3-carboxamide derivatives as potent and selective MPS1 kinase inhibitors.
    Caldarelli M; Angiolini M; Disingrini T; Donati D; Guanci M; Nuvoloni S; Posteri H; Quartieri F; Silvagni M; Colombo R
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4507-11. PubMed ID: 21723120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of novel 7-substituted pyrido[2',3':4,5]furo[3,2-d]pyrimidin-4-amines and their N-aryl analogues and evaluation of their inhibitory activity against Ser/Thr kinases.
    Deau E; Loidreau Y; Marchand P; Nourrisson MR; Loaëc N; Meijer L; Levacher V; Besson T
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6784-8. PubMed ID: 24176400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.